The global Pharma industry is under serious pressure. Large numbers of forthcoming patent expiries, a dry pipeline of new drugs, regulatory challenges and pricing restrictions have slowed down the growth of Pharma industry’s main markets. This has led to a shift in gravity towards emerging markets like India, China, South America and Russia. Emerging markets will be the next major growth drivers for the global Pharma industry, with more than 40% of incremental growth of the industry coming from emerging economies in the next decade. In this report we focus on the domestic Indian Pharma market; we believe that the domestic market has the potential to reach $74 billion by 2020 from its current size of $12 billion - a CAGR of 20%.
We take a detailed look at developments in key growth segments:
We believe that the domestic Indian pharmaceutical market has a positive growth trajectory, but will also face major transformational challenges in the next decade. We address some of these challenges and identify key imperatives to accelerate the domestic market’s growth.